• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: KANEKA CORPORATION LIXELLE BETA2-MICROGLOBULIN APHERESIS COLUMN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

KANEKA CORPORATION LIXELLE BETA2-MICROGLOBULIN APHERESIS COLUMN Back to Search Results
Model Number S-15
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Chest Pain (1776); Dyspnea (1816); Fatigue (1849); Low Blood Pressure/ Hypotension (1914); Respiratory Distress (2045); Low Oxygen Saturation (2477)
Event Date 03/15/2018
Event Type  Injury  
Manufacturer Narrative
It was reported that upon the initiation of the treatment with the lixelle, the dialyzer used was switched to fb-130pb with a larger surface area from fb-110pb (nipro).She complained pains in the chest to the back with chills in the 1st treatment (5 days before the day of this reported event) with the lixelle and had respiratory distress with chills in the 2nd (2 days before).On her show up for the treatment on the day of the reported event, she had a feeling of fatigue, with the body temperature: 37.5 degrees, blood pressure: 110/45 mmhg, pulse: 75/min, spo2: 95%, weight gain from the treatment: 2.6kg.No history of allergy.No particular adverse event has ever occurred in hemodialysis procedures in the past.However, she appealed strong indefinite complaints, anxiety and self-assertion, and was difficult to accept treatment policies.In the past several months, anorexia had continued, and there were signs of heart failure due to pleural effusion based on the chest radiograph and increase in ctr.We speculate possible causes of this reported event as follows: due to the increase in the total priming volume by the change in the dialyzer with a larger surface area and adding the lixelle, the patient was in the situation where hypotension was likely to occur more than before.After starting the hemodialysis with adding the lixelle, the targeted dehydration seemed not have achieved and the amount of body fluid gradually increased, which might have resulted in worsening in congestion of the lungs and/or pulmonary edema to develop chest pain and dyspnea.The patient's physical conditions on the day of the reported event was deteriorated and it worsened the situation.In conclusion, we determine this reported adverse event was caused not by the devices used including the lixelle but by the patient's physical conditions and intolerability to the procedure.
 
Event Description
The subject was a (b)(6)-year-old female on chronic hemodialysis (3 times a week) for 40 years.The lixelle s-15, beta2-microglobulin adsorption column, was introduced for the treatment of her dialysis related amyloidosis (dra).The lixelle is used to add in the hemodialysis circuit usually before a dialyzer in every hemodialysis procedure.During the 3rd treatment with the lixelle on (b)(6) 2018, she developed dyspnea with hypotension in 40 minutes after initiating the treatment.Oxygen supply was started (spo2 was 83%) and the dehydration on the hemodialysis was stopped.Although the oxygen supply was continued her respiratory distress persisted.In about 135 minutes after the initiation of the treatment, her bp had risen to 140mmhg, spo2 had reached 99%, the hydration procedure was resumed.Her respiratory distress persisted, her body temperature raised to 38.0 degrees, and the treatment was terminated in 45 minutes after resuming the procedure.After the treatment, the patient could not stand up by herself.Because of strong fatigue and high inflammatory response, she was hospitalized after er visit.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LIXELLE BETA2-MICROGLOBULIN APHERESIS COLUMN
Type of Device
BETA2-MICROGLOBULIN APHERESIS COLUMN
Manufacturer (Section D)
KANEKA CORPORATION
2-3-18
nakanoshima, kita-ku
osaka-city, osaka 530-8 288
JA  530-8288
Manufacturer Contact
kazuhiko inoue
2-3-18
nakanoshima, kita-ku
osaka-city, osaka 530-8-288
JA   530-8288
4613072
MDR Report Key7410392
MDR Text Key104799446
Report Number3002808904-2018-00005
Device Sequence Number1
Product Code PDI
UDI-Device Identifier14993478020218
UDI-Public14993478020218
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
H130001
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Reporter Occupation Physician
Type of Report Initial
Report Date 03/16/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberS-15
Device Catalogue NumberN/A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 03/16/2018
Initial Date FDA Received04/09/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
Patient Age74 YR
Patient Weight41
-
-